Related Experiment Video
Updated: Jan 27, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Cystic fibrosis in the modern therapeutic era: Give the shower a thought!
Déborah Le Pennec1, Melisande Baravalle-Einaudi2, Christian Dupont3
1INSERM U1100, Respiratory Diseases Centre, Tours University, Tours, France.
Abstract:
Fifty-two meshes of e-flow rapid® were characterized for tobramycin delivery with a laser diffractometer after 6 months of home use by cystic fibrosis patients treated with various nebulized drugs. Three meshes were out of order and 30 considered to be defective for tobramycin delivery. The use of the specific mesh cleaning shower system permitted 14 defective meshes to be in the expected range of nebulized volume.
Insights
Home use of e-flow rapid® meshes by cystic fibrosis patients led to significant defects in tobramycin delivery. A specialized cleaning system helped restore some defective meshes to expected performance levels.
Area of Science:
- Medical device engineering
- Pharmaceutical science
- Respiratory medicine
Background:
- Cystic fibrosis (CF) treatment often involves nebulized medications like tobramycin.
- e-flow rapid® is a mesh nebulizer system used for drug delivery in CF patients.
- Long-term performance and reliability of nebulizer components are crucial for effective treatment.
Purpose of the Study:
- To characterize the tobramycin delivery performance of e-flow rapid® meshes after prolonged home use in cystic fibrosis patients.
- To assess the impact of home use and cleaning protocols on mesh functionality.
Main Methods:
- Fifty-two e-flow rapid® meshes were tested using laser diffractometry.
- Meshes were characterized after 6 months of home use by CF patients on various nebulized therapies.
- Defective meshes were identified based on tobramycin delivery parameters.
Main Results:
- Out of 52 meshes, 3 were non-functional, and 30 were deemed defective for tobramycin delivery.
- Utilizing a specific mesh cleaning shower system allowed 14 of the defective meshes to meet expected nebulized volume ranges.
Conclusions:
- Prolonged home use of e-flow rapid® meshes can lead to a high rate of defects impacting tobramycin delivery.
- A dedicated cleaning system shows potential in restoring the functionality of some defective meshes, improving drug delivery consistency.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Modern Molecular Taxonomy
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Microorganisms in Medicine and Therapeutics

